PHARMACOKINETICS

Single-dose pharmacokinetics of co-crystal of tramadol–celecoxib: Results of a four-way randomized open-label phase I clinical trial in healthy subjects

Correspondence Sebastián Videla, MD PhD, Co-crystal Clinical Project Leader, Clinical Pharmacologist, Clinical Investigation Department, Laboratorios Dr ESTEVE, S.A.U, Av Mare de Déu de Montserrat 221, Barcelona 08041, Spain. Tel.: +34 93 446 6000; Fax: +34 93 446 6110; E-mail: svidela@esteve.es; sebastia.videla@upf.edu

Received 25 April 2017; Revised 22 June 2017; Accepted 30 July 2017

Sebastián Videla1, Mounia Lahjou2, Anna Vaqué1, Mariano Sust1, Mercedes Encabo1, Lluis Soler1, Artur Sans1, Eric Sicard3,*, Neus Gascón1, Gregorio Encina1 and Carlos Plata-Salamán1

1Laboratorios del Dr Esteve, S.A.U., Barcelona, Spain, 2Algorithme Pharma, Laval, Canada, and 3Algorithme Pharma, Montreal, Canada

*Clinical Principal Investigator.

Keywords celecoxib, co-crystal, pain, pharmacokinetics, tramadol

AIMS

Co-crystal of tramadol–celecoxib (CTC) is a novel co-crystal molecule containing two active pharmaceutical ingredients under development by Esteve (E-58425) and Mundipharma Research (MR308). This Phase I study compared single-dose pharmacokinetics (PK) of CTC with those of the individual reference products [immediate-release (IR) tramadol and celecoxib] alone and in open combination.

METHODS

Healthy adults aged 18–55 years were orally administered four treatments under fasted conditions (separated by 7-day wash-out period): 200 mg IR CTC (equivalent to 88 mg tramadol and 112 mg celecoxib; Treatment 1); 100 mg IR tramadol (Treatment 2); 100 mg celecoxib (Treatment 3); and 100 mg IR tramadol and 100 mg celecoxib (Treatment 4). Treatment sequence was assigned using computer-generated randomization. PK parameters were calculated using noncompartmental analysis with parameters for CTC adjusted according to reference product dose (100 mg).

RESULTS

Thirty-six subjects (28 male, mean age 36 years) participated. Tramadol PK parameters for Treatments-1, –2 and –4, respectively, were 263, 346 and 349 ng ml\(^{-1}\) (mean maximum plasma concentration); 3039, 2979 and 3119 ng h ml\(^{-1}\) (mean cumulative area under the plasma concentration–time curve); and 2.7, 1.8 and 1.8 h (median time to maximum plasma concentration). For Treatments 1, 3 and 4, the respective celecoxib PK parameters were 313, 449 and 284 ng ml\(^{-1}\); 2183, 3093 and 2856 ng h ml\(^{-1}\); and 1.5, 2.3 and 3.0 h. No unexpected adverse events were reported.

CONCLUSION

PK parameters of each API in CTC were modified by co-crystallization compared with marketed formulations of tramadol, celecoxib, and their open combination.

DOI:10.1111/bcp.13395 © 2017 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT

- Pharmaceutical co-crystals are usually composed of an active pharmaceutical ingredient (API) with a neutral guest compound (excipient, conformer) in a crystal lattice.
- A new generation of co-crystals containing two APIs are now in development (API–API co-crystals).
- Co-crystal of tramadol–celecoxib (CTC) is the first API–API co-crystal to show synergistic analgesic effects in preclinical studies.

WHAT THIS STUDY ADDS

- Co-crystallizing tramadol and celecoxib modifies the PK profile of each API compared with the reference products (immediate-release tramadol or celecoxib) alone or in open combination.
- CTC is a different concept from previously reported co-crystals of increases of the blood levels of an API from the levels of the API itself, but without clinical benefit since the dose needs to be adjusted in a proportional way. By contrast, in CTC, none of the three active therapeutic moieties (tramadol (+)-enantiomer μ agonist and inhibitor of 5-hydroxytryptophan reuptake, tramadol (–)-enantiomer inhibitor of NE reuptake, and celecoxib inhibitor of cyclooxygenase-2) show an increased exposure levels compared to the individual moieties, but rather they show a change in their profile that translates into clinical benefits.

Tables of Links

| TARGETS | LIGANDS |
|---------|---------|
| G protein-coupled receptors [2] | tramadol |
| μ receptor | cyclooxygenase |
| 5-HT receptor | celecoxib |

These Tables list key protein targets and ligands in this article that are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [1], and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 [2, 3].

Introduction

Unrelieved pain is a recognized global healthcare problem, with the International Association for the Study of Pain (IASP) declaring that ‘access to pain management is a fundamental human right’ [4, 5]. Despite major advances in management, the burden of acute pain – which results from tissue and nerve damage and is normally moderate to severe in intensity and of short duration (<12 weeks) [6, 7] – remains great. For example, over half of patients experience severe or intolerable levels of pain after surgery or trauma [5]. The consequences of poorly controlled acute pain include an increased risk of progression to chronic pain. Surveys have consistently shown that chronic pain affects between one in four and one in three adults [8]. The impact of chronic pain is far reaching and includes both direct and indirect economic costs. One study reported that the estimated costs associated with chronic pain in the USA exceeded 550 billion USD in 2010, similar to the combined costs for heart disease, cancer and diabetes [9].

Multimodal therapy – i.e. combined use of two or more analgesic drugs targeting different pain pathways, or different points within a pathway – is a viable strategy for improving pain management as it may result in additive or even synergistic analgesia [10]. Coadministration of two different drugs in open combination is a simple way to achieve multimodal therapy, although this approach increases the pill burden for patients and the costs of treatment, and, since in general it uses the approved doses of the individual agents, this may result in more adverse events. Fixed-dose combination (FDC) drugs containing two active pharmaceutical ingredients (APIs) are also available; however, the creation of new FDCs can be difficult due to issues with stability and solubility. Moreover, FDCs using similar amounts of approved individual APIs may result in more adverse events while often only producing sub-additive analgesia.

The development of co-crystal drugs containing two or more APIs is a new approach that has been extensively investigated in recent years as a means to circumvent these problems and potentially provide benefits above those offered by other multimodal strategies [11]. The European Medicines Agency recently published a reflection paper in which co-crystals were defined as ‘crystalline structures made up of two or more components in a definite stoichiometric ratio…’ [12]. In the pharmaceutical setting, at least one of the components is an API while the other(s) may be a nonactive coformer or excipient, or another API. API–API co-crystals may enhance the physiochemical properties, pharmacokinetic (PK) profile and ultimately the efficacy and/or safety of each API, without requiring chemical modifications [11].

Co-crystal of tramadol–celecoxib (CTC) is a novel, patented, first-in-class, API–API co-crystal that contains the analgesic drugs tramadol and celecoxib and is under development by Esteve Pharmaceuticals (as E-S8425) and Mundipharma Research (as MR308). CTC contains racemic tramadol hydrochloride (rac-tramadol.HCl) and celecoxib at an intrinsic 1:1 molecular ratio (1:1.27 weight ratio) and is formulated as an immediate-release (IR) tablet. Four different mechanisms of action for analgesia in central and...
Peripheral pathways are captured by inclusion of tramadol and celecoxib in CTC. Tramadol (+)-enantiomer acts as a mu agonist and inhibitor of 5-hydroxytryptophan reuptake, tramadol (–)-enantiomer as inhibitor of norepinephrine reuptake [13], and celecoxib as inhibitor of cyclooxygenase-2 [14].

When administered alone in its conventional form, tramadol is absorbed quickly and rapidly distributed with an elimination half-life \((T_{\text{1/2e}})\) of 5–6 h. The main active metabolite of tramadol, (+)-O-desmethyl-tramadol (M1), has a much greater affinity for the mu-opioid receptor than tramadol itself [13]. Celecoxib reaches peak plasma concentrations 2–3 h after administration of its commercially available formulation and is primarily eliminated by metabolism with an elimination half-life of 8–12 h [14]. Intrinsic dissolution rate studies have demonstrated the potential of a form of CTC co-crystal without additives to improve the dissolution profiles of both tramadol and celecoxib [15], the latter of which is a Biopharmaceutics Classification System Class II compound. When CTC was administered in suspension (‘CTC悬’ in a rat postoperative pain model, it exerted a synergistic analgesic effect compared with its reference products (i.e. it showed efficacy greater than that expected by adding together the analgesic effects observed with \(\text{rac-tramadol.HCl}\) and celecoxib alone). This synergistic effect on efficacy was achieved without an increase in adverse effects [16].

In vitro data have shown that the co-crystal structure of CTC modifies the physicochemical properties and intrinsic dissolution profiles of each of the APIs (tramadol and celecoxib) [15] and preclinical pharmacological studies also show that the intrinsic 1:1 molecular ratio of CTC is the optimal ratio for best efficacy and safety [16]. Hence, the unique characteristics of CTC are hypothesized to translate into clinical benefits in efficacy and safety.

The main objective of this Phase I study was to compare the single-dose PK profile of CTC with that of the individual authorized reference products (IR tramadol or celecoxib alone) and the open combination of IR tramadol and celecoxib. Secondary objectives included evaluation of the safety and tolerability of CTC after single-dose administration.

## Methods

### Study subjects

Healthy adults aged 18–55 years with body mass index \(\geq 18.5\) and \(<29.0 \text{ kg m}^{-2}\) were eligible for the study if they were non-ex-smokers and in good health as determined by medical history review, physical examination, electrocardiogram (ECG) and clinical laboratory tests. Key exclusion criteria included: pregnancy or lactation in females; history of severe hypersensitivity reactions to any drug; conditions known to interfere with the PK profile of the study drugs; and a significant history of drug dependency or alcohol abuse. Full inclusion and exclusion criteria can be found in Appendix S1.

### Study design and treatments

This was a Phase I, randomized, open-label, four-period, four-sequence, crossover study carried out in a single centre in Canada. Four single-dose treatments were administered orally under fasted conditions. The treatment sequence for each participant was assigned by a computer-generated randomization list. Each treatment period was separated by a 7-day wash-out period (Figure 1). The four treatments were: Treatment 1: 2 × 100 mg IR CTC tablets (200 mg; equivalent to 88 mg \(\text{rac-tramadol.HCl}\) and 112 mg celecoxib: proposed marketed formulation); Treatment 2: 2 × 50 mg IR tramadol capsules (\(\text{rac-tramadol.HCl}\); 100 mg; Adolonta, Grünenthal GmbH, Germany); Treatment 3: 1 × 100 mg celecoxib capsule (100 mg; Celebrex, Henrick Marck Nachf. GmbH & Co., KG, Germany); and Treatment 4: open combination of 100 mg tramadol (\(\text{rac-tramadol.HCl}\); 2 × 50 mg IR capsules) and 100 mg celecoxib (1 × 100 mg capsule). Tablets and capsules were swallowed whole. Subjects fasted overnight for at least 10 h prior to drug administration and for at least 4 h post-dose, after which controlled food intake was allowed. Subjects were also required to fast at least 12 h prior to the last blood sample. Alcohol, grapefruit-, pomelo- or xanthine-containing food or drink, and noninvestigator-approved prescription medications or over-the-counter products were to be avoided during the study.

The study protocol was approved by an institutional review board (project number 1975, approved on 17 December...
2010 by ETHIPRO, Montreal, Quebec, Canada) and was conducted in accordance with Good Clinical Practice, the requirements of the Declaration of Helsinki and relevant US, European and Canadian regulations/directives. All subjects provided written informed consent.

**PK sampling and analytical methods**

For treatments-1, -2 and -4, blood samples for determination of tramadol and M1 were collected prior to drug administration and at the following times postdose: 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.33, 2.67, 3, 4, 6, 8, 10, 12, 16, 24 and 36 h. For determination of celecoxib concentrations for treatments-1, -3 and -4, samples were collected pretreatment and at 0.5, 1, 1.5, 2, 2.33, 2.67, 3, 3.33, 3.67, 4, 5, 6, 8, 12, 16, 24, 36 and 48 h postdose.

Blood samples were centrifuged (1500 g for 10 minutes at 4°C) and collected plasma then divided into half and frozen until assayed. Samples from all subjects who received at least one study treatment were assayed. Plasma concentrations of tramadol, M1 and celecoxib were measured using validated high-performance liquid chromatography with tandem mass spectrometry methods. Sample pretreatment involved the liquid–liquid extraction of tramadol and O-desmethyl tramadol from 0.100 ml of human plasma; tramadol-D6, O-desmethyl tramadol-D6 and celecoxib-D7 were used as internal standards. These compounds were identified and quantified over a theoretical concentration range of 2.00 ng ml\(^{-1}\) to 800.00 ng ml\(^{-1}\) for Tramadol, 0.500 ng ml\(^{-1}\) to 200.000 ng ml\(^{-1}\) for O-desmethyl tramadol and 3.00 ng ml\(^{-1}\) to 1200.00 ng ml\(^{-1}\) for celecoxib. Assay specificity was evaluated using six independent matrix sources to verify the absence of interference, compared with respective limits of quantitation at retention time, and mass transitions of analytes and internal standards. Quantitation was made using peak area ratios, and back-calculated concentrations were determined using least squares regression analysis employing a weighted (1/x2) linear regression (\(y = mx + b\)).

**Safety assessments**

Safety assessments, including the reporting and recording of adverse events (AEs), measurement of standard clinical laboratory parameters, physical examination (including vital signs) and 12-lead ECG, were performed throughout the study. AEs were classified by system organ class and preferred term using the Medical Dictionary for Regulatory Activities, version 12.1.

**Data and statistical analyses**

**Sample size determination.** The PK profile of celecoxib is known to be more variable than that of tramadol. Based on previous findings, the intrasubject variation following a single dose of celecoxib was estimated to be around 27% for \(C_{\text{max}}\) and around 11% for \(AUC_{\tau}\). Statistically, given that the expected ratio of geometric least squares (LS) means should fall within 95% and 105%, it was estimated that 32 subjects would be sufficient to provide an adequate assessment of the pharmacokinetic and safety profiles of CTC and evaluate possible drug interactions between tramadol and celecoxib. Therefore, the inclusion of 36 subjects was deemed sufficient to take into account the possibility of drop-outs and variations around the estimated intrasubject coefficient of variation to perform a confirmatory study (pivotal Phase I study).

**PK.** Calculated PK parameters included maximum plasma concentration (\(C_{\text{max}}\)), time to maximum measured plasma concentration (\(T_{\text{max}}\)), cumulative area under the plasma concentration–time curve (\(AUC_{\infty}\)), area under the plasma concentration–time curve extrapolated to infinity (\(AUC_{\infty}\)), relative percentage of \(AUC_{\infty}\) with respect to \(AUC_{\tau}\) (\(AUC_{\infty} / AUC_{\tau}\)), apparent elimination rate constant (\(K_{\text{el}}\)), \(T_{\text{1/2}}\), apparent volume of distribution (\(V_{\text{pD}}\)) and apparent plasma clearance (\(CI_{\text{p}}\)). The natural logarithmic (ln) transformation normalized by the dose of \(C_{\text{max}}, AUC_{\tau}\) and \(AUC_{\infty}\) as well as the rank-transformation of \(T_{\text{max}}\) were used for all statistical inference.

A noncompartmental approach with a log-linear terminal phase assumption was used to estimate the PK parameters. \(AUC_{\tau}\) was determined using the trapezoidal rule and the terminal phase was estimated by maximizing the coefficient of determination from the log-linear regression model. All In-transformed PK parameters were statistically analysed using an analysis of variance model. The fixed factors included in this model were treatment, treatment period and treatment sequence as well as the left-over interaction terms between the three factors. A random factor was added for the subject effect (nested within the sequence). The sequence, period and treatment effects were assessed at the 5% two-sided level. Furthermore, the 90% confidence intervals (CIs) for the exponential of the difference in LS means between CTC and the other treatments was calculated for the ln-transformed parameters. All subjects who provided evaluable PK data for a particular treatment were included in the descriptive analysis of that treatment. For each treatment-group comparison, subjects who provided measurable PK data for both treatments were included in the PK and statistical analyses. Statistical analyses of PK data were generated using Kinetic, a validated software developed at Algorithme Pharma and SAS® version 9.1 or higher (SAS Institute, Cary, NC, USA).

Safety: Safety data were analysed using descriptive statistics. Safety was assessed in all subjects who received at least one dose of any study treatment.

**Results**

**Subjects**

Thirty-six subjects were enrolled between 23 March and 29 April 2011, of whom most were male (78%) and white (86%). Mean age was 36 years. Other demographic data are shown in Table 1. All subjects provided measurable PK data for at least two treatments and were therefore included in the PK evaluation and statistical analyses. Plasma samples collected from one subject during the first treatment period were excluded from analysis because a gastrointestinal AE occurring after administration of study treatment (open combination of tramadol and celecoxib) may have influenced PK findings. All subjects were included in the safety analysis. Four subjects withdrew or were withdrawn before study.
end, due to positive alcohol test, un-cooperative behaviour, withdrawn consent or decreased haemoglobin levels (one subject each). These subjects did not receive treatment during study period 4; therefore, the statistical analysis only included 34 subjects for Treatment 1 and 35 subjects for Treatments-2, –3 and –4.

**PK**

**PK of tramadol, M1 and celecoxib after administration of CTC.** PK parameters for tramadol, M1 and celecoxib after single-dose administration of CTC are summarized in Table 2. Plasma concentration–time profiles for each of these analytes after administration of CTC are shown in Figures 2–4, alongside the profiles observed with the reference products alone or in open combination.

**Tramadol PK.** Following PK parameters adjusted according to reference dose, mean tramadol $C_{\text{max}}$ after a single dose of CTC was lower than with tramadol alone or the open combination of tramadol and celecoxib (263.23 vs. 345.78 and 349.38 ng ml$^{-1}$, respectively; Table 3). In contrast, similar values were obtained for mean AUC$_{\tau}$ and AUC$_{\infty}$ for all three treatments. For tramadol AUC$_{\tau}$ and AUC$_{\infty}$, but not $C_{\text{max}}$, 90% CIs of the LS means ratios for CTC compared with tramadol alone or tramadol plus celecoxib were within the equivalence range of 80–125%. Median $T_{\text{max}}$ for

![Figure 2](image-url)

**Figure 2** Mean plasma concentration vs. time profiles for tramadol following a single dose of CTC (Treatment 1), tramadol alone (Treatment 2) or the open combination of tramadol and celecoxib (Treatment 4). CTC, co-crystal of tramadol–celecoxib

### Table 1
Subject demographics ($n = 36$)

| Characteristic | Value |
|---------------|-------|
| Age, years    | 36 (9.0) |
| Sex, n (%)    |       |
| Male          | 28 (77.8) |
| Female        | 8 (22.2)  |
| Race; n (%)   |       |
| White         | 31 (86.1) |
| Black         | 3 (8.3)  |
| American Native | 1 (2.8) |
| Other         | 1 (2.8)  |
| Weight, kg    | 72.4 (11.8) |
| Height, cm    | 171.4 (8.6) |
| Body mass index, kg m$^{-2}$ | 24.53 (2.9) |

Data are mean (standard deviation) unless otherwise stated.

### Table 2
Summary of pharmacokinetic parameters for tramadol, M1 and celecoxib following a single dose of CTC

| Parameter          | Tramadol ($n = 34$) | M1 ($n = 34$) | Celecoxib ($n = 34$) |
|--------------------|---------------------|--------------|----------------------|
| $C_{\text{max}}$ (ng ml$^{-1}$) | 231.65 (20.2) | 48.821 (43.0) | 350.93 (28.9) |
| $T_{\text{max}}$ (h)* | 2.67 (1.00–6.00) | 4.00 (2.00–8.00) | 1.50 (1.00–5.00) |
| AUC$_{\tau}$ (ng h ml$^{-1}$) | 2674.50 (29.5) | 713.428 (31.1) | 2444.73 (24.3) |
| AUC$_{\infty}$ (ng h ml$^{-1}$) | 2778.50 (31.2) | 752.219 (30.1) | 2756.08 (24.8) |
| $K_{\text{el}}$ (h$^{-1}$) | 0.10 (17.2) | 0.09 (18.6) | 0.05 (41.8) |
| $T_{\text{el}}$ (h) | 6.96 (18.1) | 7.82 (17.7) | 16.91 (45.7) |
| Cl/F (l h$^{-1}$) | 35.06 (34.8) | 134.81 (48.7) | 43.50 (28.8) |
| $V_d/F$ (l) | 339.86 (27.1) | 1567.51 (60.5) | 1028.33 (45.7) |

*For $T_{\text{max}}$, median and range are presented. AUC$_{\tau}$, area under the plasma concentration–time curve extrapolated to infinity; AUC$_{\infty}$, cumulative area under the plasma concentration–time curve; Cl/F, apparent plasma clearance; $C_{\text{max}}$, maximum plasma concentration; CTC, co-crystal of tramadol–celecoxib; CV, coefficient of variation; $K_{\text{el}}$, apparent elimination rate constant; M1, (+)-O-desmethyl-tramadol; CTC, co-crystal of tramadol–celecoxib; CV, coefficient of variation; $K_{\text{el}}$, apparent elimination rate constant; M1, (+)-O-desmethyl-tramadol; $T_{\text{el}}$, terminal elimination half-life; $T_{\text{el}}$, time to maximum plasma concentration; $V_d/F$, apparent volume of distribution.
Tramadol after single-dose CTC was slightly delayed (at 2.67 h vs. 1.75 h) for both tramadol alone and tramadol plus celecoxib.

M1 PK. After PK parameters had been adjusted according to reference dose, mean M1 \( C_{\text{max}} \) after a single dose of CTC was lower than after treatment with tramadol alone or tramadol plus celecoxib (55.48 vs. 73.54 and 68.34 ng ml\(^{-1}\), respectively; Table 4). For M1 AUC\(\tau\) and AUC\(\infty\), similar values were obtained with all three tramadol-containing treatments. As observed with tramadol, 90% CIs of the LS mean ratios for M1 (CTC vs. tramadol alone or tramadol plus celecoxib) were within 80–125% for AUC\(\tau\) and AUC\(\infty\) but not for \( C_{\text{max}} \). Median \( T_{\text{max}} \) for M1 was 2.33 h for tramadol and 2.60 h for tramadol plus celecoxib.

As shown in Figure 4, a pronounced decrease in celecoxib \( C_{\text{max}} \) was observed with the open combination (vs. 88 mg tramadol and 112 mg celecoxib).

Figure 4

Mean plasma concentration vs. time profiles for celecoxib following a single dose of CTC (Treatment 1), celecoxib alone (Treatment 3) or the open combination of tramadol and celecoxib (Treatment 4).

Table 3

Summary and statistical comparison of key tramadol pharmacokinetic parameters following single doses of CTC (Treatment 1), tramadol alone (Treatment 2) or the open combination of tramadol and celecoxib (Treatment 4)

| Parameter | Treatment 1200 mg CTC\(^a\) (n=34\(^b\)) | Treatment 2100 mg tramadol (n = 35) | Treatment 4100 mg tramadol + 100 mg celecoxib (n = 35) | Ratio of geometric LS means (90% CI) |
|-----------|---------------------------------|---------------------------------|------------------------------------------------|---------------------------------|
| \( C_{\text{max}} \) (ng ml\(^{-1}\)) | 263.23\(^c\) 20.2\(^c\) | 345.78 23.2 | 349.38 23.9 | 75.85 (72.11–79.79) 76.35 (72.58–80.32) 100.66 (95.74–105.82) |
| \( \text{AUC} \) (ng h ml\(^{-1}\)) | 3039.21\(^c\) 29.5\(^c\) | 2979.01 31.9 | 3119.37 28.4 | 100.55 (97.11–104.10) 98.21 (94.85–101.69) 97.68 (94.38–101.10) |
| \( \text{AUC}_{\infty} \) (ng h ml\(^{-1}\)) | 3157.38\(^c\) 31.2\(^c\) | 3060.66 33.4 | 3202.99 29.7 | 101.41 (97.83–105.12) 99.27 (95.77–102.91) 97.89 (94.48–101.43) |
| \( T_{\text{max}} \) (h)\(^d\) | 2.67 1.00–6.00 | 1.75 1.00–4.00 | 1.75 0.75–2.67 | – – – |

\(^a\)Equivalent to 88 mg tramadol and 112 mg celecoxib.

\(^b\)Three subjects did not receive treatment during study period 4; therefore, the analysis only included 34 subjects for Treatment 1 and 35 for Treatments 2 and 4.

\(^c\)Parameters for Treatment 1 were adjusted according to reference dose.

\(^d\)Median and minimum-maximum values shown. \( \text{AUC}_{\infty} \) area under the plasma concentration–time curve extrapolated to infinity; \( \text{AUC}_{\tau} \), cumulative area under the plasma concentration–time curve; \( \text{CI} \), confidence interval; \( C_{\text{max}} \), maximum plasma concentration; CTC, co-crystal of tramadol–celecoxib; \( CV \), coefficient of variation; LS, least squares; \( T_{\text{max}} \), time to maximum plasma concentration.
### Table 4

Summary and statistical comparison of key M1 pharmacokinetic parameters following single doses of CTC (Treatment 1), tramadol alone (Treatment 2) or the open combination of tramadol and celecoxib (Treatment 4).

| Parameter | Treatment 1 | Treatment 2 | Treatment 3 | Treatment 4 |
|-----------|-------------|-------------|-------------|-------------|
| \( C_{\text{max}} \) (ng ml\(^{-1}\)) | 68.34 | 43.06 | 31.11 | 30.2 |
| CV (%) | 35.5 | 42.3 | 32.6 | 20.4 |
| AUC \( \tau \) (ng h ml\(^{-1}\)) | 844.77 | 851.78 | 854.79 | 862.28 |
| CV (%) | 36.6 | 32.6 | 30.1 | 27.4 |
| AUC \( \infty \) (ng h ml\(^{-1}\)) | 97.32 | 92.98 | 95.79 | 92.08 |
| CV (%) | 30.1 | 30.1 | 29.2 | 29.4 |
| \( T_{\text{max}} \) (h) | 2.33 | 3.00 | 2.00 | 1.00 |

- Treatment 1: 200 mg CTC (88 mg tramadol plus 100 mg celecoxib)
- Treatment 2: 200 mg tramadol alone
- Treatment 3: 100 mg celecoxib alone
- Treatment 4: 100 mg CTC (88 mg tramadol plus 112 mg celecoxib)

| Parameter | Treatment 1 | Treatment 2 | Treatment 4 |
|-----------|-------------|-------------|-------------|
| \( C_{\text{max}} \) (ng ml\(^{-1}\)) | 3093.36 | 2855.97 | 2182.79 |
| CV (%) | 30.9 | 33.6 | 30.2 |
| AUC \( \tau \) (ng h ml\(^{-1}\)) | 448.87 | 318.56 | 285.76 |
| CV (%) | 30.1 | 30.1 | 29.4 |
| AUC \( \infty \) (ng h ml\(^{-1}\)) | 14.56 | 13.05 | 11.76 |
| CV (%) | 30.1 | 30.1 | 29.4 |
| \( T_{\text{max}} \) (h) | 0.75 | 2.33 | 1.00 |

- \( C_{\text{max}} \): maximum plasma concentration
- AUC: area under the plasma concentration-time curve
- \( T_{\text{max}} \): time to maximum plasma concentration

**Safety**

Twenty-nine (80.6%) subjects each reported one or more AE. The number of subjects who reported AEs after administration of each treatment was 15 (44.1%), 14 (40.0%), 12 (34.3%) and 22 (61.1%) for CTC, tramadol alone, celecoxib alone and tramadol plus celecoxib, respectively. AEs considered to be treatment-related occurred in 12 (35.3%), 14 (40.0%), 8 (22.9%) and 22 (61.1%) subjects, respectively. The most commonly reported AEs were somnolence, dizziness and nausea (Table 6). No serious AEs or deaths were reported. Two subjects had abnormal laboratory values; one had elevated hepatic enzyme levels (at a poststudy visit) and one decreased haemoglobin levels (pretreatment period 4; the subject was discontinued from the study). No clinically significant on-study vital sign abnormalities were recorded. One subject had an abnormal poststudy ECG measurement that was subsequently classified as an on-study AE (ventricular extrasystoles).

**Discussion**

The multifactorial nature of pain makes the concept of employing multiple mechanisms of analgesia within a single molecule an attractive one [17]. CTC is an API–API co-crystal of tramadol and celecoxib in development for the treatment of acute pain. This Phase I study compared the single-dose PK profile and evaluated the safety and tolerability of CTC compared with each reference product alone and with these products in open combination. The four-way design of this trial also allowed for intra- and interindividual heterogeneity to be assessed.

After adjusting for the different doses of tramadol in 200 mg CTC (88 mg) and reference tramadol (100 mg), tramadol from CTC showed a similar AUC but a lower \( C_{\text{max}} \) compared with tramadol taken alone or in open combination with celecoxib. In addition, tramadol \( T_{\text{max}} \) was slightly prolonged with CTC relative to the other tramadol-containing treatments. Similar observations were made for the main metabolite of tramadol M1. Observed PK parameters for tramadol alone were similar to those seen following coadministration of tramadol and celecoxib in this study, and are also comparable to those reported in the literature...
Table 5
Summary and statistical comparison of key celecoxib pharmacokinetic parameters following single doses of CTC (Treatment 1), celecoxib alone (Treatment 3) or the open combination of tramadol + 100 mg celecoxib (Treatment 4)

| Parameter | Treatment 1200 mg CTC \((n=34)^b\) | Treatment 3100 mg celecoxib \((n=35)\) | Treatment 4100 mg tramadol + 100 mg celecoxib \((n=35)\) | Ratio of geometric LS means (90% CI) |
|-----------|-------------------------------|---------------------------------|--------------------------------|----------------------------------|
| \(C_{\text{max}}\) (ng ml\(^{-1}\)) | 313.33 \(^c\) 28.9\(^c\) | 448.87 33.4 | 284.35 43.0 | 71.84 (64.16–80.44) 117.76 (105.15–131.89) 163.92 (146.56–183.35) |
| \(AUC\) (ng h ml\(^{-1}\)) | 2182.79 \(^c\) 24.3\(^c\) | 3093.36 23.1 | 255.97 27.4 | 71.53 (67.45–74.76) 78.97 (75.56–82.53) 110.39 (105.68–115.32) |
| \(AUC_{\text{e}}\) (ng h ml\(^{-1}\)) | 2460.79 \(^c\) 24.8\(^c\) | 3195.32 22.7 | 3121.09 25.9 | 76.42 (73.20–79.78) 79.20 (75.79–82.76) 103.64 (99.37–108.09) |
| \(T_{\text{max}}\) (h) \(^d\) | 1.50 1.00–5.00 | 2.33 1.00–5.00 | 3.00 1.00–1.200 | – – – |

\(^a\)Equivalent to 88 mg tramadol and 112 mg celecoxib.
\(^b\)Three subjects did not receive treatment during study period 4; therefore, the analysis only included 34 subjects for Treatment 1 and 35 for Treatments 3 and 4.
\(^c\)Parameters for Treatment 1 were adjusted according to reference dose.
\(^d\)Median and minimum-maximum values shown. \(AUC_{\text{e}}\), area under the plasma concentration–time curve extrapolated to infinity; \(AUC\), cumulative area under the plasma concentration–time curve; CI, confidence interval; \(C_{\text{max}}\), maximum plasma concentration; CTC, co-crystal of tramadol–celecoxib; CV, coefficient of variation; LS, least squares; \(T_{\text{max}}\), time to maximum plasma concentration.

There is a growing number of reports in the literature of co-crystals exhibiting different characteristics to the reference products alone, both in vitro and in vivo. The solubility of celecoxib was improved when produced as a co-crystal with meloxicam, indicating that the dissolution and absorption of celecoxib may be predicted to improve the safety profile of a drug.

The most common AEs reported after use of IR tramadol were related side effects [18]. Consistent with this, somnolence, mouth, sweating and fatigue are other common tramadol-related side effects [18]. There is a growing number of reports in the literature of co-crystals exhibiting different characteristics to the reference products alone, both in vitro and in vivo. The solubility of celecoxib was improved when produced as a co-crystal with meloxicam, indicating that the dissolution and absorption of celecoxib may be predicted to improve the safety profile of a drug.
antileukaemic activity when tested in vitro [25]. Improvements in the solubility and dissolution of baicalein when tested as a co-crystal with nicotinamide translated into a 2.5-fold greater C<sub>max</sub> and 2.8-fold greater AUC when administered to rats [26]. Data on the one multidrug co-crystal to have been approved to date, Entresto (Novartis, Basel, Switzerland; that by chemical analysis is a complex comprised of anionic forms of sacubitril and valsartan plus sodium cations, and water molecules) show that one of the component APIs (valsartan) has improved bioavailability compared with reference valsartan, that is, according to the Entresto label, ‘26 mg, 51 mg and 103 mg of valsartan in Entresto is equivalent to 40 mg, 80 mg and 160 mg of valsartan in other marketed tablet formulations, respectively’. Therefore, the amount of valsartan in Entresto is adjusted based on the doses used of valsartan alone.

It is important to recognize that changes in dissolution, absorption and bioavailability profiles do not necessarily mean that there is an improved clinical or therapeutic benefit; for instance, in the examples that result in increased exposures compared to the individual drugs, there is no better clinical benefit per se since to maintain efficacy and to manage safety issues, the dose needs to be adjusted in a proportional way, as commented above.

CTC presents a different and unique case. Neither tramadol nor celecoxib from CTC show increased exposure levels compared to the individual tramadol or celecoxib, but rather they both show a change in their PK profiles that may translate into clinical benefits. Essentially, data collected in the current study demonstrates that co-crystallization improves the PK properties of both constituent APIs in CTC. The intrinsic CTC structure contains the two enantiomers of tramadol, its HCl counterpart and celecoxib. The various moieties are linked via ionic and hydrogen bonding where chloride ions establish three key intermolecular contacts with the adjacent molecules [15]. The different ionic and hydrogen bonds confer upon CTC the ability to release both tramadol and celecoxib at rates and profiles that are different from a combination approach or from the individual APIs. The Phase I data are consistent with the in vitro data that showed that the intrinsic dissolution rate of tramadol HCl is slowed down (which leads to a more sustained release, longer T<sub>max</sub> and a reduction of C<sub>max</sub>) while that of celecoxib is accelerated (which leads to a faster rate of absorption).

There are some limitations to this study. The intrinsic 1:1 molecular ratio of tramadol to celecoxib in CTC means that the 200-mg dose used is equivalent to 88 mg tramadol and 112 mg celecoxib. As such, PK parameters adjusted according to reference dose calculations had to be performed to compare the PK properties of CTC and the approved doses of reference tramadol and celecoxib (both 100 mg). Furthermore, since this was the first four-way clinical trial in the CTC clinical development programme, the changes in PK parameters observed (arising from the co-crystal nature of CTC) need to be reproduced in other studies before they can be confirmed. In fact, the results of another Phase I study of CTC that used

| System organ class | Adverse event | Treatment 1200 mg CTC<sup>a</sup> (n = 34) | Treatment 2100 mg tramadol (n = 35) | Treatment 3100 mg celecoxib (n = 35) | Treatment 4100 mg tramadol + 100 mg celecoxib (n = 36) |
|-------------------|--------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| Nervous system disorders | Dizziness | 4 / 5 | 4 / 4 | 1 / 1 | 7 / 8 |
| | Headache | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 |
| | Somnolence | 8 / 8 | 10 / 10 | 5 / 5 | 10 / 11 |
| Gastrointestinal disorders | Abdominal pain | 0 | 2 / 2 | 0 | 0 |
| | Nausea | 3 / 4 | 4 / 6 | 0 | 5 / 7 |
| Respiratory, thoracic and mediastinal disorders | Nasal congestion | 1 / 1 | 1 / 1 | 1 / 1 | 0 |
| | Dysphonia | 0 | 1 / 1 | 1 / 1 | 0 |
| | Rhinitis | 0 | 0 | 1 / 1 | 1 / 1 |
| | Rhinorrhoea | 0 | 0 | 1 / 1 | 1 / 1 |
| Injury, poisoning and procedural complications | Vessel puncture site pain | 0 | 0 | 2 / 2 | 1 / 1 |
| | Vessel puncture site reaction | 3 / 3 | 1 / 1 | 1 / 1 | 0 |
| General disorders and administration site conditions | Fatigue | 0 | 2 / 2 | 0 | 0 |
| | Feeling abnormal | 0 | 1 / 1 | 0 | 1 / 1 |
| Psychiatric disorders | Euphoric mood | 1 / 1 | 2 / 2 | 0 | 0 |
| Skin and subcutaneous tissue disorders | Rash | 0 | 0 | 1 / 1 | 1 / 1 |

Data shown are number of subjects/number of events.
<sup>a</sup>Equivalent to 88 mg tramadol and 112 mg celecoxib.

AE, adverse event; CTC, co-crystal of tramadol–celecoxib
single and multiple doses are now available and support the current findings [Co-submitted manuscript by our group].

In summary, the results of this Phase I study in healthy volunteers suggest that the PK profiles of both APIs in CTC (tramadol and celecoxib) are modified by co-crystallization (compared with marketed formulations of tramadol and celecoxib and their open combination). It is possible that these PK effects may have favourable clinical implications although studies in patients experiencing pain are required to test this hypothesis fully. A randomized placebo-controlled Phase II trial comparing CTC with tramadol alone in patients with acute pain after oral surgery has now been completed [27] and Phase III trials are ongoing.

Competing Interests

S.V., A.V., M.S., M.E., A.S., N.G., G.E. and C.P. are employees of Laboratorios del Dr Esteve, S.A.U. L.S. was an employee of Laboratorios del Dr Esteve, S.A.U. when the study was performed. M.L. and E.S. are employees of Algorithm Pharma.

The study was funded by Laboratorios del Dr Esteve, S.A.U. (Barcelona, Spain) and carried out by Algorithme Pharma, a clinical research organization (Laval, Canada). Medical writing support was provided by Joanna Chapman, PhD (Aspire Scientific Ltd, Bollington, UK) and was funded by Mundipharma Research GmbH & Co. KG (Limburg, Germany). Monitoring support was provided by Vahé Bartekian and Vatché Bartekian (Vantage Biotrias, Montreal, Canada).

The authors acknowledge the following employees from Laboratorios del Dr Esteve for their contribution to this study: Gemma Casadevall, Carmen Santano, Ángel Santanach, Imma Cervera (Pharmaceutical Innovation); Esther Ortiz, Alberto Puyada (Clinical Investigation); Carmen Garcia (R&D Portfolio Management); Marisol Escriche, Santiago Puig, Josep Maria Cendrós (ADME and Bioanalysis) and Fiona Camacho (Quality Assurance).

Contributors

S.V., M.L., A.V., M.S., L.S., N.G., G.E. and C.P. were involved in the conception and design of the study and the analysis and interpretation of data. A.S., M.E. and E.S. were involved in the acquisition of data. All authors revised the article critically for important intellectual content and gave final approval of the version to be published.

References

1 Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SPH, et al. The IUPHAR/BPS guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 2016; 44: D1054–68.

2 Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE, et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein coupled receptors. Br J Pharmacol 2015; 172: 5744–869.

3 Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, et al. The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 2015; 172: 6024–109.

4 International Association for the Study of Pain. Declaration of Montréal. Declaration that access to pain management is a fundamental human right. 2010. Available at http://www.iasp-pain.org/DeclarationofMontreal?navItemNumber=582 (last accessed 09 August 2016).

5 International Association for the Study of Pain (IASP), European Federation of IASP Chapters. Factsheet 4A: unrelieved pain is a major global healthcare problem. 2005. Available at http://www.iasp-pain.org/files/Content/ContentFolders/GlobalYearAgainstPain2/20042005RighttoPainRelief/factsheet.pdf (last accessed 09 August 2016).

6 British Pain Society. FAQs. 2014. Available at https://www.britishpainsociety.org/media-resources/ (last accessed 05 August 2016).

7 Wuhrman E, Cooney MF. Acute pain: assessment and treatment. 2011. Available at http://www.medscape.com/viewarticle/735034 (last accessed 05 August 2016).

8 Breivik H, Eisenberg E, O’Brien T. The individual and societal burden of chronic pain in Europe: the case for strategic prioritisation and action to improve knowledge and availability of appropriate care. BMC Public Health 2013; 13: 1–14.

9 Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain 2012; 13: 715–24.

10 Meissner W, Coluzzi F, Fletcher D, Huygen F, Morlion B, Neugebauer E, et al. Improving the management of post-operative acute pain: priorities for change. Curr Med Res Opin 2015; 31: 2131–43.

11 Thipparaboina R, Kumar D, Chavan RB, Shastri NR. Multidrug co-crystals: towards the development of effective therapeutic hybrids. Drug Discov Today 2016; 21: 481–90.

12 European Medicines Agency. Reflection paper on the use of co-crystals of active substances in medicinal products. 2015. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/07/WC500189927.pdf (last accessed 05 August 2016).

13 Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokin 2004; 43: 879–923.

14 Pfizer. Summary of product characteristics for Celebrex 100 mg capsule. 2016. Available at http://www.medicines.org.uk/emc/medicine/14534 (last accessed 05 August 2016).

15 Almansa C, Mercé R, Tesson N, Farran J, Tomás J, Plata Salamán C. Co-Crystal of Tramadol Hydrochloride-Celecoxib (ctc): A Novel API-API Co-Crystal for the Treatment of Pain. Cryst Growth Des 2017; 17: 1884–92.

16 Merlos M, Portillo-Salido E, Brenchat A, Aubel B, Buxens J, Fisas À, et al. Administration of tramadol and celecoxib in a 1:1 molecular hybrids. Drug Discov Today 2016; 21: 481–90.

17 Raffa RB, Pergolizzi JV Jr, Tallarida RJ. The determination and application of fixed-dose analgesic combinations for treating multimodal pain. J Pain 2010; 11: 701–9.

18 Actavis. Summary of product characteristics for tramadol hydrochloride 50 mg capsules. 2015. Available at http://www.medicines.org.uk/EMC/medicine/24186/SPC (last accessed 05 August 2016).
19 Moore RA, McQuay HJ. Single-patient data meta-analysis of 3453 postoperative patients: oral tramadol versus placebo, codeine and combination analgesics. Pain 1997; 69: 287–94.

20 Lee JH, Kim MJ, Yoon H, Shim CR, Ko HA, Cho SA, et al. Enhanced dissolution rate of celecoxib using PVP and/or HPMC-based solid dispersions prepared by spray drying method. J Pharm Investig 2013; 43: 205–13.

21 Gupta VR, Mutalik S, Patel MM, Jani GK. Spherical crystals of celecoxib to improve solubility, dissolution rate and micromeritic properties. Acta Pharm 2007; 57: 173–84.

22 Liu Y, Sun C, Hao Y, Jiang T, Zheng L, Wang S. Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles. J Pharm Pharm Sci 2010; 13: 589–606.

23 Chandel N, Gupta V, Pandey A, Saxena S, Choudhary S. Co-crystallization of aceclofenac and paracetamol and their characterization. Int J Pharm Life Sci 2011; 2: 1020–8.

24 Cheney ML, Weyna DR, Shan N, Hanna M, Wojtas L, Zaworotko MJ. Coformer selection in pharmaceutical cocrystal development: a case study of a meloxicam aspirin cocrystal that exhibits enhanced solubility and pharmacokinetics. J Pharm Sci 2011; 100: 2172–81.

25 Voltan R, Rimondi E, Melloni E, Gilli P, Bertolas V, Casciano F, et al. Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein mcl-1. Oncotarget 2016; 7: 18965–77.

26 Huang Y, Zhang B, Gao Y, Zhang J, Shi L. Baicalein-nicotinamide cocrystal with enhanced solubility, dissolution, and oral bioavailability. J Pharm Sci 2014; 103: 2330–7.

27 Videla S, López-Cedrún J, Burqueño M, Juárez I, Aboul Hosn S, Martín Granizo R, et al. Co-crystal of tramadol-celecoxib: efficacy and safety results from a dose-finding, randomised, double-blind, multicentre, phase II clinical trial in patients with moderate-to-severe acute pain due to an oral surgical procedure. 16th World Congress on Pain, 26–30 September 2016. Yokohama, Japan: Poster PW0293.

Supporting Information

Additional Supporting Information may be found online in the supporting information tab for this article.

http://onlinelibrary.wiley.com/doi/10.1111/bcp.13395/supinfo

Appendix S1 Selection of study population: full inclusion and exclusion criteria